News
- Author:
- Neil Osterweil
Publish date: January 11, 2018
The moderate-intensity induction and maintenance regimen induced good responses in both younger and older patients.
News
- Author:
- Neil Osterweil
Publish date: January 4, 2018
ATLANTA – Study uses next-generation DNA sequencing to predict risk of relapse in AML.
News
- Author:
- Neil Osterweil
Publish date: January 3, 2018
Small, early clinical trial tests miridesap and dezamizumab.
News
- Author:
- Neil Osterweil
Publish date: January 3, 2018
ATLANTA – Updated results from the phase 2 SORAML trial support the addition of sorafenib in younger adults with newly diagnosed AML.
News
- Author:
- Neil Osterweil
Publish date: December 27, 2017
ATLANTA – "I believe that venetoclax/rituximab should be considered as a suitable standard therapeutic option in patients with relapsed CLL."...
Video
- Author:
- Neil Osterweil
Publish date: December 12, 2017
ATLANTA – Dr. John Seymour discussed results from a study comparing bendamustine/rituximab with venetoclax/rituximab in relapsed/refractory CLL pat...
News
- Author:
- Neil Osterweil
Publish date: December 12, 2017
ATLANTA – The study included patients with new onset multiple myeloma who were not eligible for transplant.
Video
- Author:
- Neil Osterweil
Publish date: December 12, 2017
Dr. Jesus San-Miguel discusses results of the ALCYONE study and recent advances in the treatment of multiple myeloma.
News
- Author:
- Neil Osterweil
Publish date: December 11, 2017
SAN ANTONIO – PARP inhibitor talazoparib was associated with a near doubling in progression-free survival when compared with single-agent chemother...
News
- Author:
- Neil Osterweil
Publish date: December 11, 2017
SAN ANTONIO - Neither adapted disease-free survival nor overall survival were significantly better with 3 extra years of zoledronate therapy.<...
Video
- Author:
- Neil Osterweil
Publish date: December 11, 2017
Dr. Sattva S. Neelapu describes efforts to manage adverse events common to CAR T-cell therapies, notably cytokine release syndrome.
Video
- Author:
- Neil Osterweil
Publish date: December 11, 2017
Circulating tumor cells may play a role in identifying late breast cancer recurrences in otherwise asymptomatic women
News
- Author:
- Neil Osterweil
Publish date: December 10, 2017
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median o...
News
- Author:
- Neil Osterweil
Publish date: December 9, 2017
ATLANTA – Matching red cell products to sickle-cell disease patients with rare Rh antibodies can be done with a little fancy stem cell footwork and...
Video
- Author:
- Neil Osterweil
Publish date: December 9, 2017
